![Mechanism of action of PARP inhibitors and synthetic lethality. Adapted... | Download Scientific Diagram Mechanism of action of PARP inhibitors and synthetic lethality. Adapted... | Download Scientific Diagram](https://www.researchgate.net/profile/Nicolo-Battisti/publication/328279919/figure/fig2/AS:695466937298944@1542823647046/Mechanism-of-action-of-PARP-inhibitors-and-synthetic-lethality-Adapted-from-Sonnenblick.jpg)
Mechanism of action of PARP inhibitors and synthetic lethality. Adapted... | Download Scientific Diagram
![PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review) PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)](https://www.spandidos-publications.com/article_images/ol/20/4/ol-20-04-11951-g00.jpg)
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
![Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy | Future Oncology Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2016-0002/asset/images/medium/figure1.gif)
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy | Future Oncology
![BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer - EBioMedicine BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer - EBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0a0f2f1a-c834-43fd-8c01-8d9ef6ce589d/gr1_lrg.jpg)
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer - EBioMedicine
![Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer | Business Wire Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer | Business Wire](https://mms.businesswire.com/media/20180406005678/en/642388/4/3239620_Clovis_ARIEL3_Infographic_2-19-18.jpg)
Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer | Business Wire
![PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review) PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)](https://www.spandidos-publications.com/article_images/ol/20/4/ol-20-04-11951-g01.jpg)
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
![AstraZeneca-Merck & Co.'s Lynparza gets EU approval in prostate cancer | S&P Global Market Intelligence AstraZeneca-Merck & Co.'s Lynparza gets EU approval in prostate cancer | S&P Global Market Intelligence](https://www.snl.com/articles/404070639.png)
AstraZeneca-Merck & Co.'s Lynparza gets EU approval in prostate cancer | S&P Global Market Intelligence
![Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial - The Lancet Oncology Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/67ed7825-991d-4ce9-9a39-7a4e09990087/gr1.gif)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
![Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity - Porcelli - 2013 - Molecular Oncology - Wiley Online Library Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity - Porcelli - 2013 - Molecular Oncology - Wiley Online Library](https://febs.onlinelibrary.wiley.com/cms/asset/7c3d6bb1-4824-49c7-8d90-2c7b1f6259eb/mol2201373308-fig-0005-m.jpg)
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity - Porcelli - 2013 - Molecular Oncology - Wiley Online Library
![Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action | Science Translational Medicine Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action | Science Translational Medicine](https://stm.sciencemag.org/content/scitransmed/8/362/362ps17/F1.large.jpg)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action | Science Translational Medicine
![JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers | HTML JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers | HTML](https://www.mdpi.com/jcm/jcm-08-00435/article_deploy/html/images/jcm-08-00435-g001.png)
JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers | HTML
![Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332219352837-gr1.jpg)